| 1 ] 李小丝，陆一菱，张善军，等. 硫酸艾沙康唑中间体的制备工艺研究[ J ]. 华西药学杂志，2020，35（ 3 ）：240 - 243.
[ 2 ] 牛亚平，梁蓓蓓，孙 湃，等. FDA批准上市获得QIDP认证的新药概况[ J ]. 中国药物警戒，2018，15（ 9 ）：564 - 571.
[ 3 ] 沈 煜. 浅析进行药物质量控制分析方法验证的原则和项目[ J ]. 当代医药论丛，2016，14（ 11 ）：109 - 110.
[ 4 ] 元子青云，陈安九，沈怡雯，等. 三唑类抗真菌药物临床应用研究进展[ J ]. 药学与临床研究，2018（ 2 ）：49 - 53..
[ 5 ] Guinea J, Pelaez T, Recio S，et al. In vitro antifungal activities of-
isavuconazole (BAL4815), voriconazole, and fluconazole against1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species[ J ]. Antimicrobial Agents & Chemotherapy, 2008, 52( 52 ): 1 396 - 1 400.
[ 6 ] Illnait-Zaragozi M T, Martinez G F, Curfs-Breuker I, et al. In Vit-
roactivity of the new azole isavuconazole (BAL4815) comparedwith six other antifungal agents against 162 Cryptococcus neoformansi-
solates from Cuba[ J ]. Antimicrobial Agents & Chemotherapy, 2008, 52( 4 ): 1 580 - 1 582.
[ 7 ] Warn P A, Sharp A, Denning D W. In vitro activity of a new triaz-
ole BAL4815, the active component of BAL8557 (the watersoluble prodrug), againstAspergillus spp[ J ]. Journal ofAntimicrobial Chemotherapy, 2006, 57( 1 ): 135 - 138.
[ 8 ] Seifert H, Aurbach U, Stefanik D, et al. In Vitro Activities of Isav-
uconazole and Other Antifungal Agents against Candida Bloodstr-eam Isolates[ J ]. Antimicrobial Agents & Chemotherapy, 2007, 51( 5 ): 1 818 - 1 211.
[ 9 ] 顾卫青，朱 江，董先红. 广谱唑类抗真菌新药艾沙康唑[ J ]. 中国药师，2016（ 1 ）：58 - 61.
[ 10 ] 宋婷婷，冯婧劼，马 荣. 抗真菌药物艾沙康唑研究进展[ J ]. 中国新药杂志，2015（ 3 ）：69 - 71.
[ 11 ] 栾升霖，赵临襄. 艾沙康唑硫酸酯[ J ]. 中国药物化学杂志，2015（ 5 ）：24 - 29.
[ 12 ] Miceli Marisa H. Kauffman Carol A..Isavuconazole: A New Broad-
Spectrum Triazole Antifungal Agent[ J ]. Clinical Infectious Dise-
ases, 2015( 10 ): 47 - 52.
[ 13 ] 李爱娜. FNMR定量法测定氟康唑[ J ]. 华西药学杂志，2018（ 6 ）：33 - 36.
[ 14 ] Jun Ohwada, Masao Tsukazaki, Tadakatsu Hayase, et al.Design, s-
ynthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole[ J ]. Bioorganic & Medicinal Chemistry Letters, 2002( 2 ): 1 110 - 1 115.
[ 15 ] Dunne Michael W, Puttagunta Sailaja, Sprenger Craig R, Rubino Chris, et al.Extended-duration dosing and distribution of dalbava-
ncin into bone and articular tissue[ J ]. Antimicrobial agents and chemotherapy, 2015( 4 ): 488 - 491.
[ 16 ] Eugenia N, Olsufyeva Anna N, Tevyashova.Synthesis, Properties
and Mechanism of Action of New Generation of Polycyclic Glycopeptide Antibiotics[ J ]. Current Topics in Medicinal Chemistry, 2017( 19 ): 511 - 516.
[ 17 ] Muthu K. Kathiravan, Amol B. Salake, Aparna S. Chothe, etal Corrigendum to “The biology and chemistry of antifungal agents: A review” [Bioorg. Med. Chem. 20 (2012) 5 678 - 5 698][ J ]. Bioorganic & Medicinal Chemistry, 2012( 15 ): 255 - 260.
[ 18 ] Joanne Livermore, William Hope. Evaluation of the pharmacokin-
etics and clinical utility of isavuconazole for treatment of invasive fungal infections[ J ]. Expert Opinion on Drug Metabolism & Toxicology, 2012( 6 ): 147 - 153.
[ 19 ] Ulrike Holzgrabe.Quantitative NMR spectroscopy in pharmaceuti-
cal applications[ J ]. Progress in Nuclear Magnetic Resonance Spectroscopy, 2010( 2 ): 433 - 440.
[ 20 ] Prokocimer Philippe, Bien Paul, Deanda Carisa, et al.In vitro act-
ivity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections[ J ]. Antimicrobial agents and chem-
otherapy, 2012( 14 ): 1 126 - 1 130.
[ 21 ] 石 建. 三唑类抗真菌药物研究新进展[ J ]. 国外医药（抗生素分册），1998（ 2 ）：299 - 301.
[ 22 ] Lin Xu, Marc R. Muller, Xiong Yu, et al. Improved Chiral Synthe-
sis of Ravuconazole[ J ]. Synthetic Communications, 2009( 9 ): 577 - 579.
[ 23 ] Gloria M, González.In vitro activities of isavuconazole against op-
portunistic filamentous and dimorphic fungi[ J ]. Medical Mycolog-
y, 2008( 1 ): 1 210 - 1 215.
[ 24 ] Verweij, González, Wiederhold,et al.In Vitro Antifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries[ J ]. Journal of Chemotherapy, 2009( 3 ): 245 - 250. |
